TR201904224T4 - Geliştirilmiş kompleman reseptör 2 (CR2) hedefleme grupları. - Google Patents

Geliştirilmiş kompleman reseptör 2 (CR2) hedefleme grupları. Download PDF

Info

Publication number
TR201904224T4
TR201904224T4 TR2019/04224T TR201904224T TR201904224T4 TR 201904224 T4 TR201904224 T4 TR 201904224T4 TR 2019/04224 T TR2019/04224 T TR 2019/04224T TR 201904224 T TR201904224 T TR 201904224T TR 201904224 T4 TR201904224 T4 TR 201904224T4
Authority
TR
Turkey
Prior art keywords
selectively
complement receptor
targeting groups
enhanced complement
modulators
Prior art date
Application number
TR2019/04224T
Other languages
English (en)
Inventor
Kovacs James
P Hannan Jonathan
Michael Holers V
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of TR201904224T4 publication Critical patent/TR201904224T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Burada, kompleman aktivitesi modülatörlerini seçici bir şekilde iletebilen çözünebilir proteinlere yönelik bileşimler ve yöntemler sunulmaktadır. Söz konusu modülatörlerin hedeflenen şekilde iletilmesi, belirli amino asitlerin, CR2?nin en az ilk iki N-terminal SCR domenine karşılık gelen bileşimin bir hedefleme proteini kısmında seçici olarak mutasyona uğratılmasıyla gerçekleştirilir. Hedefleme kısmına dahil edilen mutasyonların belirli kombinasyonuna bağlı olarak, bir kompleman aktivitesi modülatörü, kompleman sistemi aktivasyonunun veya supresyonunun istendiği bölgelerde, belirli CR2 ligantlarına seçici bir şekilde iletilebilmektedir.
TR2019/04224T 2010-05-14 2011-05-13 Geliştirilmiş kompleman reseptör 2 (CR2) hedefleme grupları. TR201904224T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34503510P 2010-05-14 2010-05-14

Publications (1)

Publication Number Publication Date
TR201904224T4 true TR201904224T4 (tr) 2019-05-21

Family

ID=44914740

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04224T TR201904224T4 (tr) 2010-05-14 2011-05-13 Geliştirilmiş kompleman reseptör 2 (CR2) hedefleme grupları.

Country Status (18)

Country Link
US (1) US9650447B2 (tr)
EP (1) EP2569332B1 (tr)
JP (1) JP5986990B2 (tr)
KR (1) KR20130080443A (tr)
CN (1) CN103038252A (tr)
AU (1) AU2011252864B2 (tr)
BR (1) BR112012029067A2 (tr)
CA (1) CA2799192A1 (tr)
CO (1) CO6650414A2 (tr)
EA (1) EA201291241A1 (tr)
ES (1) ES2717912T3 (tr)
IL (1) IL222881A0 (tr)
MX (1) MX2012013233A (tr)
NZ (1) NZ603560A (tr)
SG (1) SG185483A1 (tr)
TR (1) TR201904224T4 (tr)
WO (1) WO2011143637A1 (tr)
ZA (1) ZA201208579B (tr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
BRPI0808227A2 (pt) 2007-03-14 2014-07-08 Taligen Therapeutics Inc Anticorpo humanizado anti-fator b
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
KR20120130748A (ko) 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
BR112013005116A2 (pt) 2010-09-03 2019-09-24 Stem Centrx Inc moduladores e métodos de uso
WO2012095519A1 (en) * 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
US20180021376A1 (en) * 2011-03-04 2018-01-25 Rare Antibody Antigen Supply, Inc. Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
JP6211701B2 (ja) 2013-08-07 2017-10-11 アレクシオン ファーマシューティカルズ， インコーポレイテッド 非典型溶血性尿毒症症候群のバイオマーカータンパク質
RU2016151761A (ru) * 2014-05-28 2018-07-03 Рэар Энтибоди Энтиджен Сеплай, Инк. Очищенные композиции белков ivig и kh для модулирования лимфоцитов и лечения вируса гепатита b
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
SG11202010596PA (en) * 2018-05-16 2020-11-27 Csl Ltd Soluble complement receptor type 1 variants and uses thereof
CN109929026B (zh) * 2019-03-15 2020-10-13 北京康普美特创新医药科技有限责任公司 人源靶向补体抑制物蛋白mCR2-DAF及应用
EP3958901A4 (en) * 2019-04-24 2023-07-19 The Trustees of the University of Pennsylvania BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES
CN110128547B (zh) * 2019-05-07 2022-07-22 北京康普美特创新医药科技有限责任公司 人源靶向补体抑制物蛋白mCR2-fH及应用
GB201912437D0 (en) * 2019-08-30 2019-10-16 Glaxosmithkline Ip Dev Ltd CR2 Binding Proteins and their use in Medical Therapy
CN111763243B (zh) * 2020-05-22 2021-01-29 浙江海洋大学 小公鱼免疫活性肽及其制备方法和用途
JP2024520497A (ja) 2021-05-28 2024-05-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｃｍ－ｔｍａバイオマーカーを検出するための方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981481A (en) 1974-12-06 1999-11-09 The Johns Hopkins University Human C3b/C4b receptor (CR1)
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
DE3830271A1 (de) 1988-09-06 1990-03-15 Goetze Otto Mittel mit immunsuppressiver wirkung
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2648133B1 (fr) 1989-06-08 1992-02-21 Sanofi Sa Lauramides n-substitues, leur preparation et compositions les contenant
US5310729A (en) 1990-04-20 1994-05-10 California Institute Of Biological Research Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
US5331090A (en) 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
DK0788513T3 (da) 1994-10-25 2001-04-02 Glaxo Group Ltd Anvendelse af bindingsmidler for CD23 i behandlingen af atoimmune sygdomme
US5922320A (en) 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
AU3487697A (en) 1996-06-14 1998-01-07 Johns Hopkins University School Of Medicine, The Use of chimeric vaccinia virus complement control proteins to inhibit complement
AU733890B2 (en) 1996-08-21 2001-05-31 Sugen, Inc. Crystal structures of a protein tyrosine kinase
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
GB9624731D0 (en) 1996-11-28 1997-01-15 Univ Leicester Complement inhibitor
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US6503947B1 (en) 1998-01-27 2003-01-07 Brigham And Women's Hospital Method of treating cytotoxic damage
EP2033659B1 (en) 1998-02-20 2013-12-04 Genentech, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU762799B2 (en) 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
EP1001021B1 (en) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
EP1176981B1 (en) 1999-05-07 2005-11-30 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7576182B1 (en) 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0008582D0 (en) 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
AU2001261103B2 (en) 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7439330B2 (en) 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
DE60219611T2 (de) 2001-02-21 2007-12-27 Alavita Pharmaceuticals, Inc., Mountain View Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
EP1387697A4 (en) 2001-05-17 2005-04-20 Jolla Pharma METHOD FOR TREATING ANTIBODY-MEDIATED DISEASES USING MEANS TO INHIBIT CD21
WO2003018774A2 (en) 2001-08-29 2003-03-06 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
EP1336618A1 (en) 2002-02-15 2003-08-20 HANS-KNÖLL-INSTITUT FÜR NATURSTOFF-FORSCHUNG e.V. Porcine complement regulator factor H and its use
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
WO2004045520A2 (en) 2002-11-15 2004-06-03 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP2006523199A (ja) 2003-03-28 2006-10-12 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 末梢神経疾患の治療及び／又は予防のためのクラステリンの使用
WO2004103288A2 (en) 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
JP4029772B2 (ja) 2003-05-16 2008-01-09 株式会社日立製作所 磁気ヘッドおよびそれを用いた磁気記録再生装置
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP1682179A4 (en) 2003-11-05 2008-09-03 Palingen Inc INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
CA2554729A1 (en) 2004-01-27 2005-08-11 University Of Southern California Polymer-bound antibody cancer therapeutic agent
PL1713503T3 (pl) 2004-02-10 2014-02-28 Univ Colorado Regents Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP5622351B2 (ja) 2004-09-03 2014-11-12 クレアビリス・セラピューティクス・エスピーエー プロテアーゼ抵抗性ヒトおよび非ヒトＨＭＧＢ１Ｂｏｘ−Ａ変異体、ならびにそれらの治療／診断への使用
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN101142321B (zh) 2004-11-18 2012-06-06 耶鲁大学 治疗眼病的方法和组合物
US20110020237A1 (en) 2005-01-14 2011-01-27 Glabe Charles G Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders
CA2597411C (en) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US20090087907A1 (en) 2005-07-29 2009-04-02 Alice Pebay Compositions and Methods for Growth of Pluripotent Cells
EP1922062A2 (en) 2005-09-08 2008-05-21 DSMIP Assets B.V. Method of treatment or prevention of age-related macular degeneration
EP1933870A2 (en) 2005-09-19 2008-06-25 Palingen Inc. Treatment of b cell diseases using anti-germline antibody binding agents
KR20130137716A (ko) 2005-11-04 2013-12-17 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
WO2007112403A2 (en) 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
PT2044111E (pt) * 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
US7705475B2 (en) 2006-08-03 2010-04-27 Stats Chippac Ltd. Integrated circuit package system
EP2097455B1 (en) 2006-11-02 2014-10-22 Genentech, Inc. Humanized anti-factor d antibodies
BRPI0808227A2 (pt) 2007-03-14 2014-07-08 Taligen Therapeutics Inc Anticorpo humanizado anti-fator b
JP5683265B2 (ja) 2007-06-07 2015-03-11 ジェネンテック， インコーポレイテッド 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
AR069130A1 (es) 2007-11-02 2009-12-30 Novartis Ag Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
AU2008351988B2 (en) 2008-03-03 2013-07-25 Novelmed Therapeutics, Inc. Anti-properdin antibodies
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
WO2010033868A2 (en) * 2008-09-19 2010-03-25 Taligen Therapeutics, Inc. Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
WO2010091183A2 (en) 2009-02-04 2010-08-12 The Regents Of The University Of Colorado, A Body Corporate Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
KR20120130748A (ko) 2009-11-05 2012-12-03 알렉시온 캠브리지 코포레이션 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
CN103248395A (zh) 2012-02-09 2013-08-14 中兴通讯股份有限公司 一种窄带干扰抑制方法及装置
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody

Also Published As

Publication number Publication date
CN103038252A (zh) 2013-04-10
IL222881A0 (en) 2012-12-31
EP2569332B1 (en) 2019-01-09
KR20130080443A (ko) 2013-07-12
ES2717912T3 (es) 2019-06-26
JP5986990B2 (ja) 2016-09-06
WO2011143637A1 (en) 2011-11-17
EP2569332A4 (en) 2013-10-23
US20130190477A1 (en) 2013-07-25
SG185483A1 (en) 2012-12-28
EA201291241A1 (ru) 2013-05-30
BR112012029067A2 (pt) 2019-09-24
US9650447B2 (en) 2017-05-16
MX2012013233A (es) 2013-05-20
ZA201208579B (en) 2015-05-27
NZ603560A (en) 2014-09-26
JP2013529202A (ja) 2013-07-18
AU2011252864A1 (en) 2012-11-29
EP2569332A1 (en) 2013-03-20
CA2799192A1 (en) 2011-11-17
CO6650414A2 (es) 2013-04-15
AU2011252864B2 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
TR201904224T4 (tr) Geliştirilmiş kompleman reseptör 2 (CR2) hedefleme grupları.
HRP20191305T1 (hr) Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
BR112015004696A2 (pt) polipeptídeos quiméricos tendo especificidade de ligação alvejada
NZ623086A (en) Therapeutic peptides
BR112013003361A2 (pt) anticorpo, polinucleotídeo e polipeptídeo isolado, composição, vetor, célual hospedeira, método de produção de um anticorpo, conjugado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos de tratamento, de indução e de diagnóstico de doença em um indivíduo
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
WO2016022994A3 (en) High affinity pd-1 agents and methods of use
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
PE20142114A1 (es) Polipeptidos de receptores de activina variantes, solos o en combinacion con quimioterapia, y sus usos
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
TR201910686T4 (tr) Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
WO2008036929A3 (en) Complex for transferring an anionic substance into a cell
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
NZ737844A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
IN2014KN01713A (tr)
MX336391B (es) Metodos y composiciones que usan polipeptidos de fusion de fgf23.
TR201908367T4 (tr) Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi
MX2014011459A (es) Proteinas nutritivas cargadas y metodos.
MX366155B (es) Celulas para producir iduronato-2-sulfatasa recombinante.
IN2013MN00188A (tr)
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
MX2012012928A (es) Composiciones y metodos de uso para anticuerpos terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.